Lupin gets tentative USFDA approval to market generic valbenazine capsules
- Country:
- India
Pharmaceuticals firm Lupin Ltd on Monday said it has received tentative approval from the US health regulator to market its generic valbenazine capsules used to treat involuntary movements of the face, tongue or other body parts.
The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of valbenazine capsules of strengths 40 mg, 60 mg and 80 mg, the company said in a regulatory filing. These are the generic equivalent of Ingrezza capsules, 40 mg, 60 mg, and 80 mg, of Neurocrine Biosciences, Inc, it added.
Valbenazine capsules had estimated annual sales of USD 1,235 million in the US, the company said, citing IQVIA MAT December 2022 data.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Ingrezza
- USFDA
- Valbenazine
- Neurocrine Biosciences
- Inc
- Lupin Ltd
- ANDA
ALSO READ
Strides Pharma receives approval from the USFDA for new antidepressant medication
Natco Pharma Receives Warning Letter from USFDA for Telangana Manufacturing Facility
Gland Pharma gets USFDA nod for generic breast cancer drug
Lupin, Glenmark recall drugs in US market: USFDA
USFDA issues warning letter to Kilitch Healthcare for Navi-Mumbai plant